Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Irfan Vaziri (NPI 1811900244)

Field	Value
Entity Type	Individual
Organization	Irfan Vaziri
Address	4101 Tiger Lily Rd Ste 100
City	Lincoln
State	NE
ZIP	68516
Taxonomy	Medical Oncology Physician
NPI Enumerated	August 15, 2006

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider reports Total Medicare revenue: $1.4M and Total Medicaid revenue: none (no Medicaid billing on file), making the practice effectively single‑payer with Medicare as the dominant revenue source. Absence of Medicaid billing on file indicates payer mix is heavily concentrated on Medicare beneficiaries rather than dual or Medicaid populations.

Revenue is highly concentrated in a small set of infusion drugs: Top 3 Medicare codes by revenue account for 76.9% of this provider's total Medicare revenue, led by J9271 which alone generates $782.6K (55.5% of Medicare revenue). The reliance on a few high‑value drug codes creates sensitivity to changes in drug pricing, reimbursement, or utilization of those specific agents.

The code mix (J9271, J9144, J1569 and multiple chemotherapy administration codes such as 96413, 96365 and 96417) identifies this practice as an oncology‑focused infusion operation that administers high‑cost biologics and monoclonal antibodies and provides on‑site chemotherapy services. Supportive care and infusion‑related services are also present (for example J2506, J0185, and administration/add‑on codes), indicating integrated drug administration and follow‑up E/M visits rather than a purely consultative practice.

Competitive standing for the top drug is middle‑of‑the‑pack nationally: J9271 (pembrolizumab) is $782.6K of revenue and ranks #493 of 1841 providers nationally (73th percentile; typical, unremarkable volume for this code), which suggests respectable but not market‑leading volume for this specific immunotherapy. By contrast J9144 (daratumumab) accounts for $191.5K and ranks #483 of 615 (19th percentile; typical, unremarkable volume for this code), signaling relatively low national share among daratumumab providers, while J1569 (immune globulin) sits at a modest national position (rank #310 of 542, 43th percentile).

Office visit E/M activity is notable relative to national peers: 99214 accounts for $56.1K and 638 claims and ranks #31627 of 479517 providers nationally (93th percentile; notably above typical national volume for this code). This elevated 99214 volume suggests the provider sustains a higher‑than‑typical level of established‑patient management, consistent with ongoing treatment and follow‑up for chronic oncology patients.

There are operational utilization patterns worth attention: J1439 appears with 21.8K claims but a $1 avg paid/claim and $21.8K revenue (1.5% of Medicare revenue) and ranks #770 of 1209 providers nationally (35th percentile; typical, unremarkable volume for this code), reflecting a very high claim count with minimal per‑claim payment that may represent low‑reimbursed supply or small‑unit billing rather than a high‑revenue drug line. Monitoring claim composition and unitization for such items may clarify resource and revenue drivers.

Tenure is long: NPI enumerated (registered) 2006-08-15 (~20 years ago), indicating an established provider with a multi‑year billing history in Medicare. That longevity supports interpretation of observed patterns as stable practice behavior rather than a short‑term anomaly.

Overall business implication: with $1.4M in Medicare revenue concentrated in expensive oncology biologics (J9271, J9144) and no Medicaid activity, this provider operates as a Medicare‑facing oncology infusion practice where drug mix and administration volume drive financial performance. Payer negotiations, drug acquisition and inventory management, and capacity for infusion services will be the primary levers affecting revenue and margins for this practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

68 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,200	$40	$782.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,040	$40	$191.5K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,080	$40	$110.9K
J0897	Injection, denosumab, 1 mg	4,380	$20	$78.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	640	$90	$56.1K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	420	$90	$38.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	250	$90	$22.5K
J1439	Injection, ferric carboxymaltose, 1 mg	21,750	$1	$21.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	130	$130	$16.8K
J0185	Injection, aprepitant, 1 mg	9,100	$1	$9.1K

Showing 1–10 of 68

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Irfan Vaziri — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

68 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	30	14,400	$40	$671.6K
J9144	11	10	10,440	$40	$434.6K
J1569	8	10	5,980	$40	$224.3K
J0897	43	200	2,040	$20	$62.7K
J2506	11	20	460	$90	$40.5K
J1439	18	30	25,880	$1	$26.4K
J9217	51	50	110	$130	$20.6K
J0885	13	10	3,180	$10	$19.2K
96413	31	80	60	$90	$18.2K
99214	220	3,210	110	$70	$14.9K

Showing 1–10 of 68

Related Providers

Other providers that share a Tax Identification Number (TIN) with Irfan Vaziri, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
The Physician Network	NE	Family Medicine Physician	$0	$3.1M
Eric Avery	NE	Hematology & Oncology Physician	$3.1M	$0
Kailash Mosalpuria	NE	Hematology & Oncology Physician	$2.9M	$0
Chi Health Clinic Specialty, LLC	NE	Hospitalist Physician	$0	$2.6M
Madhu Midathada	NE	Hematology & Oncology Physician	$2.3M	$0
Scott Mcham	NE	Hematology & Oncology Physician	$1.9M	$0
Sakeer Hussain	IA	Hematology & Oncology Physician	$1.9M	$0
Phelps Memorial Health Center	NE	Critical Access Hospital	$0	$1.8M

Nearby Providers

Other providers in the same ZIP code as Irfan Vaziri, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Melvin Churchill	NE	Rheumatology Physician	$4.8M	$0
Lincoln Radiology Group PC	NE	Diagnostic Radiology Physician	$0	$4.5M
Elite Professionals Home Care LLC	NE	Home Health Agency	$0	$4.2M
Rick Chatwell	NE	Rheumatology Physician	$3.5M	$0
Lincoln Pediatric Group LLC	NE	Pediatrics Physician	$0	$2.3M
Nebraska House Call Physicians, P.C.	NE	Internal Medicine Physician	$0	$1.7M
Steven Dunder	NE	Hematology & Oncology Physician	$1.7M	$0
Urology Surgical Center LLC	NE	Ambulatory Surgical Clinic/Center	$1.4M	$190.5K
Wallace Peterson	NE	Hematology & Oncology Physician	$1.5M	$0
Stacey Knox	NE	Hematology & Oncology Physician	$1.4M	$0

Irfan Vaziri — Billing Profile & Reimbursement Data

Sign up for Irfan Vaziri — Billing Profile & Reimbursement Data policy alerts

Irfan Vaziri — Billing Profile & Reimbursement Data

Sign up for Irfan Vaziri — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References